What is the success rate of Cabometyx (cabozantinib)?

Drugs.com

Official answer

by Drugs.com

Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used to treat certain patients with advanced renal cell carcinoma, hepatocellular (liver) cancer, or advanced or metastatic differentiated thyroid cancer.

It is a chemotherapy drug that you take until your cancer starts to get worse - disease progression - or you can no longer tolerate the drug because of side effects or adverse reactions.

How successful Cabometyx is can be measured by how long patients take the treatment for, how long they survive for without their cancer getting worse (progression-free survival), how many months they remain alive for while taking the treatment and how many patients respond to the drug.

How effective is Cabometyx?

Trial Duration of treatment Median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR)
METEOR - advanced renal cell carcinoma Cabometyx: 7.6 months (range 0.3 - 20.5) vs Everolimus (Afinitor): 4.4 months (range 0.21 - 18.9) PFS Cabometyx: 7.4 months (95% CI 5.6, 9.1) vs Everolimus: 3.8 months (95% CI 3.7, 5.4)

OS Cabometyx: 21.4 months (95% CI 18.7, NE) vs Everolimus: 16.5 months (95% CI 14.7, 18.8)

ORR Partial responses only Cabometyx: 17% (95% CI 13%, 22%) vs Everolimus: 3% (95% CI 2%, 6%)
CABOSUN - advance renal cell carcinoma Cabometyx: 6.5 months (range 0.2 - 28.7) vs Sunitinib (Sutent): 3.1 months (range 0.2 - 25.5) PFS Cabometyx: 8.6 months (95% CI 6.8, 14.0) vs Everolimus: 5.3 months (95% CI 3.0, 8.2)

ORR Partial responses only Cabometyx: 20% (95% CI 12%, 30.8%) vs Everolimus: 9% (95% CI 3.7%, 17.6%)
CHECKMATE-9ER - advanced renal cell carcinoma, first-line treatment Cabometyx plus nivolumab (Opdivo): 14 months (range 0.2 - 27) PFS Cabometyx: 16.6 months (95% CI 12.5, 24.9) vs Sunitinib: 8.3 months (95% CI 7.0, 9.7)

OS Cabometyx: Not reached vs Sunitinib: Not reached

ORR Complete and partial responses Cabometyx: 55.7% (95% CI 50.1, 61.2) vs Sunitinib: 27.1% (95% CI 22.4, 32.3)
CELESTIAL - advanced hepatocellular carcinoma Cabometyx: 3.8 months (range 0.1 - 37.3) vs Placeo: 2.0 months (range 0.0 - 27.2) PFS Cabometyx: 5.2 months (95% CI 4.0, 5.5) vs Placebo: 1.9 months (95% CI 1.9, 1.9)

OS Cabometyx: 10.2 months (9.1, 12.0) vs Placebo: 8.0 months (6.8, 9.4)

ORR Partial responses only Cabometyx: 4% (95% CI2.3, 6.0) vs Placebo: 0.4% (95% CI 0.0, 2.3)
COSMIC-311 - radioiodine-refractory differentiated thyroid cancer previously treated with VEGFR-targeted therapy PFS (updated analysis) Cabometyx: 11 months (95% CI 7.4, 13.8) vs Placebo: 1.9 months (95% CI 1.9, 3.7)

ORR (updated analysis) Partial responses only Cabometyx: 18% (95% CI 10%, 29%) vs Placebo: 0.0% (95% CI 0.0%, 11%)

Related medical questions

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords